Sorrento Therapeutics (SRNE) stock price, revenue, and financials

Sorrento Therapeutics market cap is $2.6 b, and annual revenue was $31.43 m in FY 2019

$2.6 B

SRNE Mkt cap, 28-Sept-2020

$9 M

Sorrento Therapeutics Revenue Q2, 2020
Sorrento Therapeutics Net income (Q2, 2020)-85 M
Sorrento Therapeutics EBIT (Q2, 2020)-47.7 M
Sorrento Therapeutics Cash, 30-Jun-202024.4 M
Sorrento Therapeutics EV2.8 B

Sorrento Therapeutics Income Statement

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q1, 2020Q2, 2020

Revenue

74.2k91.8k110.1k217.1k134.5k134.1k83.8k976.0k775.0k1.3m977.0k1.2m1.1m988.0k902.0k2.2m4.9m4.7m121.9m6.2m3.9m4.1m6.1m7.7m9.0m

Cost of goods sold

563.0k510.0k527.0k509.0k314.0k604.0k359.0k295.0k418.0k1.1m816.0k1.1m1.3m1.2m2.2m2.3m

Gross profit

413.0k265.0k749.0k468.0k859.0k499.0k629.0k607.0k1.8m3.8m3.8m120.8m4.9m2.7m1.9m3.8m

Gross profit Margin, %

42%34%59%48%73%45%64%67%81%78%83%99%79%69%47%62%

R&D expense

636.3k636.5k799.1k917.5k950.8k1.4m2.1m6.1m5.3m5.4m7.8m8.0m24.1m13.0m32.0m200.0k16.6m14.6m17.9m19.6m25.6m21.2m24.2m

General and administrative expense

527.2k159.0k218.7k244.6k427.0k1.2m1.1m3.4m2.4m1.9m2.2m3.1m4.7m4.5m4.2m5.3m11.9m9.1m10.2m10.0m11.0m20.1m25.1m26.3m24.5m

Operating expense total

1.2m795.4k1.0m1.2m1.4m2.6m3.2m10.3m8.3m7.9m10.6m11.4m36.1m25.4m47.0m15.6m27.1m17.3m23.9m37.5m32.3m52.0m127.0m47.5m48.6m

EBIT

(1.1m)(703.7k)(907.6k)(944.9k)(1.2m)(2.5m)(3.3m)(9.9m)(8.0m)(7.1m)(10.2m)(10.5m)(35.6m)(24.8m)(46.4m)(13.8m)(23.3m)(13.5m)96.9m(32.5m)(28.4m)(47.9m)(123.2m)(43.2m)(47.7m)

EBIT margin, %

(1469%)(767%)(824%)(435%)(924%)(1875%)(3947%)(1012%)(1031%)(559%)(1042%)(898%)(3231%)(2505%)(5139%)(614%)(479%)(288%)79%(521%)(725%)(1167%)(2005%)(559%)(530%)

Interest expense

9.9k223.0k45.0m2.7m

Interest income

1.7k1.4k1.5k1.8k2.1k1.9k1.7k4.0k5.0k2.0k1.0k13.0k45.0k26.0k225.0k232.0k265.0k4.0k6.0k219.0k534.0k19.0k2.0k

Investment income

(499.0k)470.0k323.0k(948.0k)(1.1m)(36.5m)(922.0k)(897.0k)(556.0k)(4.7m)

Pre tax profit

(10.6m)(11.0m)33.2m(20.0m)(46.1m)14.0m(25.5m)(16.1m)95.5m(33.6m)(74.1m)(50.4m)(145.8m)(68.9m)(82.2m)

Income tax expense

(178.0k)(17.0k)35.3m(1.7m)(1.4m)57.5m(900.0k)(1.4m)(826.0k)(178.0k)(276.0k)(1.9m)

Net Income

(1.1m)(702.3k)(906.1k)(943.1k)(1.2m)(2.5m)(3.4m)(10.1m)(8.5m)(7.6m)(10.4m)(11.0m)(939.0k)(18.4m)(44.9m)14.4m(23.1m)(14.2m)(2.1m)(32.6m)(74.8m)(50.5m)(108.1m)(69.2m)(85.0m)

Sorrento Therapeutics Balance Sheet

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

3.5m5.1m31.7m71.9m39.0m82.4m20.4m158.7m

Accounts Receivable

2.2m3.8m

Prepaid Expenses

29.9k80.9k4.9m6.6m

Current Assets

3.6m5.3m32.6m73.9m141.0m89.7m29.7m179.6m

PP&E

988.4k1.5m2.4m2.3m7.2m12.7m19.3m24.4m

Goodwill

24.0m24.0m20.6m41.5m38.3m38.3m

Total Assets

4.6m6.8m92.6m141.5m343.5m401.6m431.6m624.1m

Accounts Payable

224.7k439.5k2.2m1.7m1.3m8.3m9.9m13.8m

Short-term debt

194.6k10.2m

Current Liabilities

359.3k584.2k5.5m9.6m30.9m76.1m79.0m61.6m

Long-term debt

875.9k4.4m8.8m4.4m47.1m5.2m223.1m

Total Debt

1.1m47.1m5.2m233.3m

Total Liabilities

315.1m225.0m416.6m

Common Stock

26.2k30.0k9.0k13.0k

Preferred Stock

Additional Paid-in Capital

10.3m17.1m99.7m176.2m184.9m303.9m413.9m626.7m

Retained Earnings

(67.5m)(113.3m)(174.3m)(165.1m)(367.7m)

Total Equity

4.2m6.2m66.8m108.7m140.9m86.5m206.6m207.5m

Debt to Equity Ratio

0.2 x0.5 x

Debt to Assets Ratio

0.2 x0.1 x

Financial Leverage

1.1 x1.1 x1.4 x1.3 x2.4 x4.6 x2.1 x3 x

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q1, 2020Q2, 2020

Cash

2.9m2.3m2.4m7.6m6.4m9.6m5.8m6.4m29.9m50.2m44.3m60.5m51.7m59.1m20.8m98.2m66.5m33.9m53.7m38.3m24.3m46.8m135.4m91.0m21.9m24.4m

Accounts Receivable

657.0k576.0k986.0k784.0k898.0k622.0k1.1m867.0k526.0k2.3m2.4m1.7m3.9m7.4m10.0m13.8m

Prepaid Expenses

4.8k41.3k22.6k13.6k66.8k688.7k75.0k407.6k626.0k705.0k586.0k879.0k1.2m731.0k1.9m556.0k1.1m3.3m2.4m2.3m6.2m5.5m14.7m14.4m

Inventories

4.6m3.0m2.4m

Current Assets

3.0m2.3m2.5m7.7m6.6m10.5m5.9m6.9m31.2m51.4m45.8m62.2m53.8m124.8m71.7m146.3m71.8m42.1m60.6m44.7m36.6m54.7m145.2m118.6m49.6m55.0m

PP&E

849.5k928.0k1.2m1.2m1.3m1.5m1.4m1.7m2.4m2.3m2.4m2.5m2.8m3.8m7.4m9.2m10.1m17.0m18.0m19.0m19.5m19.9m21.5m28.9m28.5m27.5m

Goodwill

24.0m24.0m24.0m24.0m12.5m20.6m20.6m20.6m20.6m36.9m38.3m38.3m38.3m38.3m

Total Assets

3.9m3.3m3.7m8.9m7.9m12.2m7.8m38.0m90.6m110.3m104.1m131.3m132.8m325.3m273.8m351.4m279.1m345.2m384.8m448.8m436.9m452.5m588.0m609.5m536.6m533.1m

Accounts Payable

202.8k236.9k199.5k276.3k394.5k707.1k735.7k1.4m1.2m1.3m1.5m1.9m2.5m1.6m3.1m4.4m1.4m11.6m9.6m13.0m9.0m9.9m17.2m14.7m29.0m26.6m

Short-term debt

267.6k292.0k1.7m2.6m3.7m4.5m4.6m4.7m4.9m5.1m6.4m2.4m1.6m8.7m20.0m22.6m

Current Liabilities

425.0k472.0k320.0k415.7k544.2k1.3m1.5m2.3m5.3m6.9m8.7m9.4m10.4m26.1m28.4m61.0m36.0m71.8m79.3m83.4m51.5m39.4m82.4m74.1m90.1m91.3m

Long-term debt

608.3k535.3k4.8m10.3m9.4m8.4m7.7m6.9m5.6m3.1m1.8m458.0k26.1m26.5m24.6m5.5m16.2m145.5m277.3m235.1m198.2m

Total Debt

875.9k827.2k4.8m10.3m9.4m8.4m7.7m6.9m5.6m3.1m1.8m458.0k26.1m26.5m24.6m5.5m16.2m145.5m286.0m255.0m220.8m

Total Liabilities

41.6m178.5m184.8m216.2m206.6m283.1m288.6m346.5m196.0m193.1m364.4m491.4m485.3m452.9m

Common Stock

25.0k25.0k26.2k30.0k30.0k33.6k1.3k1.6k2.0k3.0k3.0k4.0k4.0k4.0k4.0k7.0k26.0k6.0k9.0k9.0k10.0k13.0k23.0k25.0k

Preferred Stock

Additional Paid-in Capital

8.1m8.2m10.4m16.4m16.5m23.8m24.0m52.4m102.1m129.4m130.0m178.0m180.2m181.7m189.8m337.0m336.6m304.6m353.2m357.9m480.7m574.3m588.9m657.1m875.7m989.7m

Retained Earnings

8.0m9.2m13.5m(59.0m)(78.0m)(88.9m)(89.9m)(131.7m)(176.7m)(162.3m)(197.3m)(211.5m)(213.6m)(196.8m)(270.6m)(318.0m)(475.8m)(725.0m)(802.8m)

Total Equity

3.5m2.8m3.4m8.5m7.3m10.3m5.8m30.9m59.2m78.0m71.0m100.0m91.3m146.8m89.0m135.2m72.5m62.1m96.2m102.3m240.9m259.5m223.6m118.1m51.2m80.2m

Debt to Equity Ratio

0.2 x0.2 x0.1 x0.1 x0.1 x0.1 x0 x0 x0 x0 x0.4 x0.3 x0.2 x0 x0.1 x0.7 x

Debt to Assets Ratio

0.1 x0.1 x0.1 x0.1 x0.1 x0.1 x0 x0 x0 x0 x0.1 x0.1 x0.1 x0 x0 x0.2 x

Financial Leverage

1.1 x1.2 x1.1 x1 x1.1 x1.2 x1.3 x1.2 x1.5 x1.4 x1.5 x1.3 x1.5 x2.2 x3.1 x2.6 x3.8 x5.6 x4 x4.4 x1.8 x1.7 x2.6 x5.2 x10.5 x6.6 x

Sorrento Therapeutics Cash Flow

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(3.2m)(4.8m)(21.9m)(34.7m)(50.1m)(63.9m)11.1m(212.5m)(363.0m)

Depreciation and Amortization

159.2k293.3k1.3m3.2m2.4m2.9m7.1m9.1m11.0m

Accounts Receivable

184.8k(18.5k)(2.2m)(515.0k)(1.6m)(10.6m)

Inventories

(3.2m)

Accounts Payable

42.9k(23.2k)878.6k(497.0k)(2.7m)3.7m1.6m3.6m10.2m

Cash From Operating Activities

(2.7m)(3.8m)(16.5m)(28.8m)(42.1m)(70.9m)(99.2m)(111.8m)(173.0m)

Purchases of PP&E

(1.1m)(547.9k)(420.2k)(591.0k)(3.7m)(6.9m)(11.0m)(11.2m)(11.4m)

Cash From Investing Activities

(1.1m)(547.9k)(503.5k)(10.6m)12.6m(17.5m)(16.5m)(21.2m)(38.2m)

Short-term Borrowings

(20.0m)

Long-term Borrowings

(53.2m)(3.1m)

Cash From Financing Activities

2.0m6.0m43.6m79.6m(3.3m)131.7m53.7m326.0m78.9m

Net Change in Cash

(1.8m)1.6m(62.0m)193.0m(132.3m)

Interest Paid

1.5m1.6m1.3m3.5m1.6m12.7m

Income Taxes Paid

800.0800.0800.06.0k3.0m2.0k34.0k6.0k13.0k

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q1, 2020Q2, 2020

Net Income

(1.8m)(2.5m)(906.1k)(1.8m)(3.1m)(2.5m)(7.3m)(10.6m)(10.1m)(18.5m)(26.2m)(10.4m)(21.4m)(23.5m)(20.0m)(66.1m)(51.9m)(23.8m)(38.5m)(37.1m)(33.5m)(108.4m)(158.8m)(146.5m)(69.2m)(154.2m)

Depreciation and Amortization

57.0k104.0k62.5k131.9k209.0k103.1k329.3k637.6k774.0k1.6m2.4m823.0k1.4m1.8m545.0k1.1m1.2m1.5m3.2m5.3m3.3m3.9m6.2m3.0m3.1m5.7m

Accounts Receivable

164.9k213.4k(11.4k)(27.4k)(24.8k)(54.3k)(13.0k)43.2k(271.0k)(191.0k)(601.0k)(56.0k)(170.0k)106.0k(273.0k)7.0k136.0k(642.0k)(680.0k)3.0k(1.7m)(3.6m)4.4m655.0k

Accounts Payable

(40.5k)(70.3k)(36.8k)51.6k169.8k253.3k296.2k824.9k(980.0k)(955.0k)(703.0k)95.0k321.0k(352.0k)1.8m3.1m38.0k2.4m(1.1m)4.6m(1.8m)(326.0k)7.2m(3.4m)728.0k(1.2m)

Cash From Operating Activities

(1.6m)(2.2m)(797.6k)(1.5m)(2.5m)(2.5m)(6.3m)(9.3m)(9.1m)(15.5m)(21.1m)(8.8m)(7.6m)(25.9m)(20.2m)(32.4m)(54.1m)(21.9m)(41.7m)(54.3m)(24.0m)(46.1m)(66.8m)(44.3m)(38.5m)(76.1m)

Purchases of PP&E

(749.1k)(810.6k)(225.5k)(310.7k)(491.1k)(157.4k)(178.2k)(359.3k)(94.0k)(198.0k)(433.0k)(343.0k)(500.0k)(1.9m)(596.0k)(2.2m)(3.7m)(4.2m)(6.8m)(9.4m)(448.0k)(2.8m)(5.7m)(5.2m)(21.0k)(970.0k)

Cash From Investing Activities

(749.1k)(810.6k)(225.5k)(310.7k)(491.1k)(207.4k)(228.2k)(744.6k)(94.0k)(198.0k)(433.0k)(1.8m)(12.0m)14.3m(596.0k)(2.2m)(5.0m)(4.2m)(10.3m)(14.9m)(448.0k)(2.8m)(15.7m)(22.3m)(21.0k)(3.3m)

Short-term Borrowings

(20.0m)

Long-term Borrowings

(827.2k)(758.0k)(1.9m)(1.2m)(2.4m)(3.7m)(21.5m)(21.5m)(21.5m)(438.0k)(59.5m)(131.9m)

Cash From Financing Activities

7.8k7.8k5.9m5.9m7.2m7.2m11.4m7.5m34.2m34.1m(711.0k)(651.0k)(1.2m)2.6m93.7m86.6m(22.5m)23.1m25.2m28.2m75.4m242.7m(1.1m)24.7m68.0m

Net Change in Cash

(2.4m)(3.0m)(1.0m)4.2m3.0m4.5m663.3k1.3m(1.7m)18.5m12.6m(11.4m)(20.2m)(12.8m)(18.2m)59.1m27.4m(48.6m)(28.9m)(44.1m)3.8m(67.7m)(13.8m)(11.4m)

Interest Paid

879.08.8k47.7k136.0k387.0k636.0k248.0k720.0k307.0k580.0k778.0k1.3m2.0m2.8m128.0k1.1m1.5m2.5m1.6m3.1m

Income Taxes Paid

800.0800.0800.0800.0800.0800.0800.06.0k6.0k6.0k3.0k1.0k1.0k1.0k30.0k34.0k15.0k15.0k

Sorrento Therapeutics Ratios

USDQ2, 2011

Financial Leverage

1.1 x

Sorrento Therapeutics Employee Rating

2.927 votes
Culture & Values
3.2
Work/Life Balance
3.5
Senior Management
2.7
Salary & Benefits
2.5
Career Opportunities
3.2
Source